Navigation Links
NewCardio Study of QTinno Accuracy Selected for Presentation at the National Scientific Meeting of the American Society of Clinical Pharmacology and Therapeutics
Date:2/8/2011

SANTA CLARA, Calif., Feb. 8, 2011 /PRNewswire/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiovascular diagnostic solutions developer, announced today that the Company has been invited to present the results of a key QTinno® performance study at the National Scientific Meeting of the American Society of Clinical Pharmacology and Therapeutics (ASCPT), to be held in Dallas, March 3-5, 2011.

The study, entitled "Intelligent Automated ECG Extraction from Continuous 12-Lead Holter Recordings Reduces Measurement Variability in Thorough QT Studies," was completed in collaboration with physician scientists from a global pharmaceutical partner. Continuous 24-hour ECG recordings (Holters) are commonly used in cardiac safety drug studies.  At present, the user visually selects three 10 second ECGs from the recording within 5 minutes of each designated study time point, a labor-intensive approach that is prone to error and variability. NewCardio has developed a novel ECG selection algorithm that evaluates the entire 10-minute window around the designated time point and selects the lowest noise and most stable ECGs in the window. The study chosen for presentation at the ASCPT meeting shows NewCardio's automated ECG selection method yields substantially more accurate and precise data than visual ECG selection.  Moreover, the accuracy gain from automated ECG selection is fully additive to the accuracy gain delivered by QTinno itself.

Dr. Ihor Gussak, NewCardio's Chief Medical Officer, commented, "We are pleased to have this opportunity to present our results on automated ECG selection at the annual ASCPT meeting. This is a prestigious and well-attended forum, and gives us an excellent opportunity to share our latest QTinno improvements and innovations with scientists and professionals from academia, drug regulatory bodies, clinical trial service providers, and the pharmaceutical industry. The data we will be presenting demonstrate that NewCardio's novel automated ECG selection algorithm substantially improves data quality in drug safety studies. Pharma sponsors can use our automated ECG selection technology and QTinno to increase study power, thereby reducing the risk of a failed study. Alternatively, the sponsor can reduce the number of subjects in a study without sacrificing study power, which may represent a substantial cost savings. We believe this is a powerful extension of our platform technology, and demonstrates NewCardio's ability to add value to every ECG."  

About QTinno TechnologyNewCardio's patented QTinno 3-D ECG software technology is a novel, fully automated program for evaluating QT and other timing intervals relevant for assessing drug cardiac toxicity in drug development. It provides fast, accurate and precise QT data from a broad range of challenging ECGs and enables reliable, automated identification of key cardiac events. Pharmaceutical sponsors and clinical research organizations, which are mandated by the FDA to test new drugs for potential cardiac toxicity, are expected to benefit from QTinno's faster, more accurate and less expensive assessment of cardiac status.

About the American Society for Clinical Pharmacology and Therapeutics (ASCPT)The American Society for Clinical Pharmacology and Therapeutics (ASCPT) consists of over 2,100 professionals committed to promoting and advancing the science and practice of human pharmacology and therapeutics, and is the largest professional organization serving the discipline of clinical pharmacology.

About NewCardio, Inc.NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-lead ECG.  NewCardio's 3-D ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect.  NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit www.newcardio.com.

Forward-Looking StatementsThis press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0Investor Contact:Hayden IRJeff Stanlis, Partner(602) 476-1821jeff@haydenir.com
'/>"/>

SOURCE NewCardio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NewCardio Presents Results for Cardiac Safety Research Consortium Blinded Drug Safety Study
2. NewCardios Chief Technical Officer, Dr. Dorin Panescu, Named 2011 IEEE Fellow
3. NewCardio Announces Financial Results for Its 2010 Third Quarter
4. NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded Testing Dataset
5. NewCardio CEO Increases Equity Position
6. NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress
7. NewCardio to Sponsor and Present at 4th Annual Cardiac Safety Assessment Summit
8. NewCardio Announces Master Services Agreement With Dedicated Phase I
9. NewCardio Leadership to Present Two Abstracts at ISCE Conference
10. Vincent W. Renz Joins NewCardio as President
11. NewCardio Announces Positive Results From Third Clinical Validation Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , December 2, 2016 bioLytical Laboratories, ein Weltführer ... bei den Mitgliedern des Apothekenbundes von Kenia eingeführt. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ...
(Date:12/2/2016)... , Dec. 2, 2016   CytoSorbents Corporation ... commercializing its European Union approved CytoSorb ® cytokine ... surgery patients worldwide, announced that Dr. Phillip Chan ... 9th Annual LD Micro Main Event investor conference ... at the Luxe Sunset Boulevard Hotel in ...
(Date:12/2/2016)... 1, 2016  Today, Simpson Healthcare Executives, a global ... being selected as winners of multiple awards at the ... at the PLATINUM level, Blue Zones Menu at the ... GOLD Level, and our proprietary 3ConneX Platform at the ... Executives, we are excited to showcase our new Platinum ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... , ... Center for Autism and Related Disorders (CARD) Portland today announced plans ... (ASD) and other developmental disabilities. The group, which is being launched with the help ... opportunity to share stories and advice, seek help, and continue their education on how ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than half of American teens report ... parents report speaking with their child about sex related topics, less than 60 percent ... is proud to announce the launch of its second edition of the “Sexual Wellness” ...
(Date:12/2/2016)... ... 02, 2016 , ... The PAINWeekEnd Regional Conference will be ... in Honolulu, offering local frontline clinicians the opportunity to extend their certified continuing ... for supplemental training related to pain management has surged dramatically in recent years, ...
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), ... night. No other wearable health technology on the market can deliver all that rejiva ... more meaningful insights about their health than the usual heart rate and steps taken”, ...
Breaking Medicine News(10 mins):